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ER Quality Control: Minireview
The Cytoplasmic Connection
Ron R. Kopito segregated from the bulk solution. Efficient targeting to
the proteasome requires that substrates be tagged withDepartment of Biological Sciences
Stanford University covalently attached multiubiquitin chains. The protea-
some cooperates with a 19S “cap” structure that recog-Stanford, California 94305-5020
nizes and removes the ubiquitin and possesses ATPase
activity that probably helps to unfold and to “feed” the
unfolded substrate into the active site. ProteasomesThe endoplasmic reticulum (ER) is the port of entry of
are abundant in the cytoplasm and nucleus, but aremembrane and secretory proteins into the central vacu-
apparently absent from the ER lumen.olar system, which includes the ER itself, the Golgi appa-
Mutations in the cystic fibrosis transmembrane con-ratus, lysosomes, endosomes, the plasma membrane,
ductance regulator (CFTR), a polytopic integral mem-and intermediate transport compartments. The ER is
brane protein, cause the human genetic disease cysticalso the site where nascent secretory and membrane
fibrosis by interfering with the biosynthetic folding ofproteins acquire their mature tertiary and quaternary
nascent CFTR polypeptides in the ER and targeting themstructures. “Quality control” mechanisms in the ER en-
for rapid destruction via a process bearing all of thesure that nascent proteins that fail to fold or to oligo-
hallmarks of classical “ER degradation” (reviewed bymerize correctly are not deployed to distal compart-
Ward and Kopito, 1996). Evidence of a role for the pro-ments of the secretory pathway and, following a lag
teasome inCFTR degradation, suggested by its sensitiv-period of variable duration, are rapidly degraded (re-
ity to inhibition by lactacystin, was strengthened by theviewed by Hammond and Helenius, 1995) (Figure 1).
discovery that undegraded CFTR molecules that accu-Because this process is independent of lysosomal func-
mulate in the presence of lactacystin are modified bytion and because degradation substrates can be local-
covalently attached multiubiquitin chains (Ward et al.,ized to the ER region by immunocytochemistry, it has
1995). Moreover, mutant CFTR molecules are stabilizedbeen generally assumed that the degradation occurs
by coexpression of UbK48R, a dominant negative formwithin the ER itself and it has been termed “ER degrada-
of ubiquitin that is unable to form multiubiquitin chains,tion” (reviewed by Klausner and Sitia, 1990). However,
and by conditional inactivation of the ubiquitin-activat-the abundance in the ER lumen of unfolded and partially
ing enzyme, E1 (Ward et al., 1995).folded polypeptide chains that are highly susceptible to
Additional evidence supporting a role for the ubiquitinproteolysis is difficult to reconcile with the presence
pathway in ER degradation was suggested by the ge-in the same compartment of an aggressive proteolytic
netic interaction between UBC6, a ubiquitin-conjugatingapparatus. Is there a proteolytic subcompartment within
enzyme that is associated with the cytoplasmic face ofthe ER into which misfolded substrates are segregated?
the ER membrane and SEC61, which encodes an ER-How does this system distinguish proteins that are in
resident polytopic integral membrane protein (Sommerthe process of folding from those that are unable to
and Jentsch, 1993). Mutant, unassembled forms offold? How can this system degrade integral membrane
Sec61p are rapidly degraded by a process requiringproteins which are exposed to three different compart-
ments (lumen, cytoplasm, and membrane)?
Considerable progress toward answering these ques-
tions has been achieved in a set of papers published in
the past year (Ward et al., 1995; Biederer et al., 1996;
Hiller et al., 1996; Qu et al., 1996; Werner et al., 1996;
Wiertz et al., 1996a, 1996b). Emerging from these studies
is a radically different model of ER degradation in which
misfolded proteins are exported or “dislocated” from
the ER and degraded by cytoplasmic proteasomes. This
model—demonstrated so far for a limited but rapidly
Figure 1. Quality Control in the Endoplasmic Reticulumgrowing set of integral membrane and soluble pro-
teins—challenges the notion of the ER as a proteolytic Nascent polypeptide chains are translocated across the ER mem-
brane through a pore (green) composed in part of the Sec61p com-organelle and the widely held assumption that transloca-
plex. Binding of molecular chaperones (red circles) and coretion of proteins into the ER is an irreversible process.
N-glycosylation occur cotranslocationally (step 1). Although severalA Role for the Ubiquitin Proteasome
classes of chaperones participate in folding and translocation, only
Pathway in ER Quality Control one is shown for simplicity. Polypeptide folding, including the forma-
The discovery that lactacystin—a fungal metabolite that tion of disulfide bonds and release from the translocation apparatus,
is accompanied by dissociation of molecular chaperones (step 2).specifically binds to and inhibits multiple proteolytic ac-
Complete dissociation from molecularchaperones and competencetivities of the mammalian proteasome (Fenteany et al.,
for packaging into transport vesicles for export to post-ER compar-1995)—is an effective inhibitor of “ER degradation,”
ments requires oligomeric assembly (step 3). Mutations or kineticallypointed a long-awaited finger at the proteasome as the
slow folding steps retard the release of the nascent chain from
culprit in this process. Proteasomes (reviewed by Coux molecular chaperones and, possibly, the translocation apparatus
et al., 1996) are cylindrical ring-like assemblies with a (step 2a). Misfolded chains remain associated with molecular chap-
erones and are prevented from exiting the ER (step 3a).central chamber into which the proteolytic active site is
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longer cosediments with membranes. These results
suggest a model in which newly synthesized HCs are
specifically dislocated from the ER by association with
the US11 or US2 proteins to the cytoplasm where they
are deglycosylated and then degraded by the protea-
some. Unlike CFTR, dislocated HC degradation interme-
diates that accumulate in US2/US11-expressing cells in
the presence of lactacystin are not detectably ubiquiti-
nated. Possibly another tag, perhaps one of the virally
Figure 2. Dislocation of Misfolded Proteins from the ER encoded proteins that appear to accompany HC to the
(A) Misfolded integral membrane proteins, associated with molecu- proteasome, may substitute for multiubiquitination in
lar chaperones are ubiquitinated by cytoplasmic enzymes and are directing some ER degradation substrates to theprotea-
dislocated through a pore that may be composed in part of the some. Alternatively, modification of HC by ubiquitin may
Sec61p translocation complex. N-linked oligosaccharides are re-
be transient and, hence, difficult to detect because ofmoved by N-glycanase activity, presumed to be present within the
the action of cellular isopeptidases and other deubiquiti-cytoplasm. The energy for disolocation could be provided by lume-
nating enzymes.nal or cytosolic chaperones, or by the unfolding ATPase activity of
the 26S proteaseome. Three recent papers now suggest that the cytoplasmic
(B) A similar pathway exists for misfolded soluble proteins that are degradation pathway is not restricted to integral mem-
translocated into the ER lumen. How these proteins are targeted to brane proteins. In one, Qu et al. (1996) report that the
the disolocation apparatus is not known. degradation of mutant secretory protein a1-antitrypsin,
which lacks a transmembrane anchor and is therefore
the function of two cytoplasmic ubiquitin-conjugating fully translocated into the ER, is inhibited by lactacystin,
enzymes, UBC6 and UBC7. The degradation of mutant suggesting the involvement of the proteasome. A sec-
unassembled forms of Sec61p is also blocked by over- ond paper (Hiller et al., 1996) shows that a mutant form
expression of UbK48R and by mutations in PRE1, which of the lumenal vacuolar enzyme carboxypeptidase Y
encodes a subunit of the proteasome, further implicating (CPY*), a protein that lacks a transmembrane domain
the ubiquitin–proteasome pathway in the process of ER and should thus be fully translocated into the ER lu-
degradation (Biederer et al., 1996). men, is degraded by a process requiring the same set
The apparent absence of proteasomes from the ER
of cytoplasmic ubiquitin-conjugating enzymes (UBC6,
lumen poses a topological problem for degradation of UBC7) that are required for Sec61p degradation. Indeed,
proteins in the ER, since some or all of these substrates
UBC7 was identified by these investigators as DER2, a
are segregated from the proteasome by a phospholipid
gene required for ER degradation of CPY*. Like CFTR
bilayer membrane. However, nearly half of CFTR’s
and Sec61p, CPY* degradation can be inhibited by coex-
amino acids are predicted to be exposed to the cyto-
pression of UbK48R. CPY* is also stabilized by muta-
plasm and could thus be substrates for ubiquitin-depen-
tions in subunits of the 20S catalytic core (PRE1) ordent proteasomal degradation. What is the fate of the
the 19S cap (CIM3) of the proteasome. Similarly, theother half of the protein, which dips into and out of the
degradation of a mutant yeast secretory protein, prepromembrane in a serpentine fashion? Does the protea-
alpha factor, is sensitive to proteasome mutations insome work like a razor, shaving off only the cytoplasmi-
vivo and to proteasome inhibitors in vitro (Werner et al.,cally exposed residues and leaving the membrane and
1996).lumenal portions to another, unidentified protease? Can
Unless proteasomes can enter the ER lumen, whichthe proteasome, known to be a highly processive en-
has not been observed, these lumenal proteins mustzyme, initiate and terminate degradation in the middle of
also be dislocated from the ER for presentation to thea polypeptide chain? Recent data suggest an alternative
cytoplasmic ubiquitin–proteasome machinery for degra-model in which ER degradation substrates must be re-
dation. Surprisingly, even though they lack membraneverse translocated or “dislocated” from the ER mem-
anchors, a1-antitrypsin, prepro alpha factor, and CPY*brane prior to presentation to the cytoplasmic degrada-
all remain tightly associated with microsomes followingtion apparatus (Figure 2).
disruption of proteasome-inhibited cells, although theirRetrograde Translocation of Proteins
susceptibility to added extravesicular proteases sug-from the ER
gests that they have been dislocated to the cytosolicOne way by which human cytomegalovirus (CMV)
side of the ER membrane. This tight association of evenevades the host immune system isby inducing the selec-
hydrophilic substrates with the ER membrane suggeststive degradation of newly synthesized class I heavy
that dislocation and degradation may be tightly coupledchains (HCs). In cells expressing either of two viral
processes.genes, US2 (Wiertz et al., 1996b) or US11 (Wiertz et al.,
Is Dislocation the Reverse of Translocation?1996a), HCs are first inserted into the ER membrane and
The notion that the ER membrane participates in thecotranslationally glycosylated but are then degraded by
retrograde translocation of proteins is not new. Proteinsan extraordinarily rapid (t1/2 , 1 min) process that is
that are unable to complete translocation have beenblocked by lactacystin and other proteasome inhibitors.
observed to accumulate at the cytoplasmic side of theAlthough initially membrane-associated and core-gly-
ER membrane as signal peptidase–cleaved intermedi-cosylated, pulse–chase studies reveal that the HC that
ates (Garcia et al., 1988; Nguyen et al., 1991). Becauseaccumulates in lactacystin-treated cells has been sub-
the active site of signal peptidase is present at the lume-jected to enzymatic deglycosylation, presumably by cy-
toplasmic N-glycanase (Suzuki et al., 1994), and no nal side of the ER membrane, these results suggest that
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at least the early steps of translocation are reversible. What sort of signal sequence directs dislocation sub-
strates to the pore? The simplest model would be ifIn addition, toxins like ricin or Shiga, which enter the
cell through endocytosis, travel in retrograde through misfolded substrates are never fully released from the
translocation apparatus. Cross-linking studies suggestthe secretory pathway to the ER and must be translo-
cated across the ER membrane to gain access to the that release of integral membrane proteins from the
translocation pore proceeds in a stepwise fashion, in-cytoplasm (Sandvig and van Deurs, 1994). The mecha-
nism of this translocation is unknown but may involve volving sequential interactions with Sec61p and TRAM
and perhaps other components (Do et al., 1996). Per-reversal of the translocation machinery, or perhaps a
distinct transport system. haps a signal such as multiubiquitination prevents a
misfolded protein from being fully released from theIn principle, the same set of general rules that govern
the translocation of proteins into the ER (and across translocation apparatus and directs it to the protea-
some. Such a situation may well operate for proteinsother membranes such as mitochondrial and bacterial
inner membranes) should apply to the process of dislo- like CFTR that expose large domains to the cytoplasmic
ubiquitination apparatus and are rapidly degraded with-cation. Thus any dislocation mechanism should satisfy
at least the following four criteria. out detectable lag. At the other extreme are secretory
proteins like prepro alpha factor, CPY*, and a1-antitryp-First, dislocation substrates should be unfolded or
loosely folded. Misfolded proteins that are destined for sin, which, when correctly processed, should be pro-
tected from the cytoplasm by the ER membrane. If thesedislocation from the ER are associated with ER chaper-
ones like BiP and calnexin, which prevent the formation polypeptides are indeed fully translocated and dissoci-
ated from the translocation apparatus, there must beof aggregates on the cis side of the ER membrane and
can be envisioned to effectively maintain the proteins an additional signal to direct them to the dislocation and
the ubiquitination machinery. The coordination betweenin a “dislocation competent” state. In CMV-infected
cells, the US2 or US11 gene products, which encode the presence of misfolded proteins in the ER and the
activation of the cytoplasmic ubiquitin machinery couldtype I integral membrane proteins could provide such
a chaperone function. involve the IRE1 gene, which encodes a transmembrane
kinase that is required for the “unfolded protein re-Second, there should be a source of energy to drive
dislocation. On the trans (i.e., cytoplasmic) side of the sponse” in which the presence of unfolded proteins
within the ER initiates the transcription of stress re-membrane, candidate ATPases that could power dislo-
cation include cytoplasmic HSP70 and the 19S cap of sponse genes in the nucleus (Cox et al., 1993). Alterna-
tively, retention of proteins in the immediate proximitythe proteasome, which possesses intrinsic unfolding
ATPase activity. Proteasomes are bound to the cyto- of thedislocation–translocation apparatus, possiblyme-
diated by an interaction between molecular chaperonesplasmic face of the ER membrane, where they could
degrade polypeptides codislocationally. The role of ER- and the dislocation apparatus, could eliminate the need
for such targeting.bound proteasomes in dislocation and degradation of
lumenal and membrane proteins is an important area Finally, how does the quality control machinery dis-
criminate between proteins that are in the process offor future investigation.
Third, there must be a transmembrane pore capable folding and those that are misfolded and should be de-
graded? Molecular chaperones like BiP and Hsp70 un-of engaging dislocating polypeptides and delivering
them to the cytoplasmic machinery. The SecY/E protein dergo cycles of ATP-dependent release from sub-
strates; rebinding thus represents a kinetic partitioncomplex, which forms the transmembrane pathway
through which exported substrates are translocated between folded and unfolded states. These chaperones
bind to folding intermediates and to misfolded proteinsacross the bacterial inner membrane, can in theabsence
of proton motive force or association with the peripheral alike, suggesting that their presence or absence from a
polypeptide chain cannot be the sole determinant ofATPase component, SecA, facilitate the backwards
translocation of substrates (Schiebel et al., 1991). Can its fate. Some additional signal, possibly ubiquitination,
must exist to allow the quality control machinery to eval-the eukaryotic homolog of SecY/E, Sec61p, also func-
tion as a bidirectional translocator? Wiertz et al. (1996b) uate the progress of the chaperone interaction and to
keep chaperones from cycling indefinitely on nonpro-reported that in US2-transfected cells treated with lacta-
cystin to block proteolysis, deglycosylated MHC class ductive substrates. Perhaps protein fate is ultimately
determined by a three-way kinetic partitioning betweenI HCs can be coimmunoprecipitated in a complex to-
gether with US2 and Sec61p, consistent with the hypoth- folding, chaperone binding, and multiubiquitination.
Eukaryotic cells have evolved an amazing variety ofesis that the Sec61p complex may provide a dislocation
pathway across the membrane. Additional studies will editing and quality control systems that monitor the fi-
delity of key molecular events such as transcription,be needed, however, to confirm whether or not those
complexes represent bona fide dislocation intermedi- replication, and translation—and protein folding. It is
now recognized that aberrant protein folding is an im-ates, and whether or not additional membrane compo-
nents are required to form the transmembrane pathway. portant etiologic factor in the pathogenesis of diseases
including cystic fibrosis, a1-antitrypsin deficiency, retini-Fourth and least well understood, there must be a
mechanism by which dislocation substrates are recog- tis pigmentosa, Alzheimer’s disease, and prion dis-
eases. The finding of a role for the ubiquitin–proteasomenized and delivered to the dislocation apparatus. Most
translocation systems require a signal on the substrate pathway in the degradation of proteins that fail to fold
productively in theendoplasmic reticulumnow adds oneprotein or on an associated protein that is recognized
by a receptor associated with the translocation pore. more function to the rapidly growing list of cellular roles
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for this versatile system and, for the first time, provides
a molecular basis for understanding the quality control
systems that operate on proteins in the secretory
pathway.
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